One-liner#

Atrial fibrillation management centers on stroke prevention with anticoagulation (based on CHA2DS2-VASc, not symptoms), rate or rhythm control for symptoms, and addressing modifiable risk factors like OSA, obesity, and alcohol.

Quick nav#

Definition and epidemiology#

Diagnostic criteria#

Atrial fibrillation is defined by irregularly irregular R-R intervals, absence of distinct P waves replaced by fibrillatory waves, and duration of 30 seconds or more on ECG.

Classification by pattern: Paroxysmal (self-terminating within 7 days), Persistent (sustained over 7 days requiring cardioversion), Long-standing persistent (continuous over 12 months), Permanent (AF accepted with no rhythm control attempts).

Valvular AF (moderate-severe mitral stenosis or mechanical valve) requires warfarin. Non-valvular AF can use DOACs.

Epidemiology#

Prevalence is approximately 6 million in US, making it the most common sustained arrhythmia. Lifetime risk is 1 in 4 adults. Age-related: under 1% at age 50, approximately 10% at age 80. Risk factors include HTN (most common), HF, valvular disease, OSA (present in over 50% of AF patients), obesity, alcohol, hyperthyroidism, and diabetes. AF causes 5-fold increased stroke risk and 15-20% of all ischemic strokes.

Pathophysiology#

Mechanism (clinical understanding)#

Triggers from ectopic foci (usually pulmonary veins) initiate AF. Atrial fibrosis, dilation, and electrical remodeling allow AF to sustain. AF begets AF: the longer it persists, the more remodeling occurs.

Stroke occurs because loss of atrial contraction causes blood stasis in the left atrial appendage, leading to thrombus formation and embolization. Stroke risk is independent of AF burden or symptoms.

Tachycardia-induced cardiomyopathy develops from sustained rapid rates over 100-110, causing LV dysfunction over weeks to months. This is often reversible with rate control.

How to explain to patients#

Your heart has a natural pacemaker that keeps it beating regularly. In AFib, the top chambers quiver chaotically instead of beating normally, making your heart beat fast and irregularly.

The main risk is stroke. When the top chambers quiver instead of squeeze, blood can pool and form clots. If a clot travels to your brain, it causes a stroke. The blood thinner prevents clots from forming.

Clinical presentation#

Characteristic symptoms#

Symptomatic AF presents with palpitations described as irregular or chaotic, fatigue, reduced exercise tolerance, dyspnea on exertion, lightheadedness, and chest discomfort. Up to 30% of AF is asymptomatic, often discovered incidentally. Stroke risk is the same regardless of symptoms.

Physical exam findings#

Irregularly irregular pulse is the hallmark finding with variable pulse amplitude. Variable S1 intensity occurs due to variable diastolic filling. Pulse deficit means apical rate exceeds radial rate. Look for signs of HF (JVD, S3, edema) and hyperthyroidism (tremor, lid lag, goiter).

Red flags#

Require urgent evaluation: hemodynamic instability, HR over 150 with symptoms, new HF symptoms, suspected stroke or TIA, WPW with AF (wide complex irregular tachycardia), and syncope with AF.

Diagnostic workup#

Initial evaluation#

All patients with new AF need: 12-lead ECG to confirm AF and rule out WPW; TSH since hyperthyroidism causes 2-5% of new AF; BMP for baseline Cr and K; CBC for anemia and baseline before anticoagulation.

Echocardiogram for all new AF to assess LV function (EF under 40% changes rate control strategy), LA size (over 5 cm predicts lower rhythm control success), and valvular disease (moderate-severe mitral stenosis requires warfarin).

Confirmatory testing#

If AF not captured on initial ECG: Holter monitor for daily symptoms, event monitor for weekly symptoms, implantable loop recorder for infrequent but high suspicion cases.

Screen for OSA with STOP-BANG; order home sleep test if score 3 or higher. OSA is present in 50-80% of AF patients and treating it improves outcomes.

When to refer for specialist workup#

Cardiology or EP referral for: rhythm control consideration, symptomatic despite rate control, HFrEF with new AF, young patient under 65, recurrent AF after cardioversion, or LAAC candidate if anticoagulation contraindicated.

What NOT to order#

TEE before starting anticoagulation is not needed. Routine Holter in known persistent AF does not change management. BNP does not confirm or exclude AF. Cardiac MRI should be reserved for specific indications.

Treatment#

Goals of therapy#

Prevent stroke by anticoagulating based on CHA2DS2-VASc score. Control symptoms with rate or rhythm control. Prevent tachycardia-induced cardiomyopathy by maintaining HR under 110. Address modifiable risk factors including OSA, obesity, HTN, and alcohol.

Non-pharmacologic management#

Weight loss of 10% reduces AF burden by 50% per LEGACY trial. Alcohol abstinence reduces AF recurrence by 50% in regular drinkers per ARREST-AF. Screen all AF patients for OSA and treat with CPAP if diagnosed. Moderate exercise of 150 minutes per week improves outcomes. Target BP under 130/80. Moderate caffeine does NOT increase AF risk.

Pharmacologic management#

Anticoagulation based on CHA2DS2-VASc: CHF (1), HTN (1), Age 75 or over (2), DM (1), Stroke/TIA (2), Vascular disease (1), Age 65-74 (1), Female (1). Anticoagulate if score 2 or higher; consider if score 1 in males. HAS-BLED identifies modifiable bleeding risks but should NOT withhold anticoagulation.

DrugDoseContraindicationsMonitoringCostNotes
Apixaban5mg BID; 2.5mg BID if 2 or more of: age 80+, weight 60kg or less, Cr 1.5+Active bleeding, mechanical valveCr annually$$Preferred DOAC; lowest bleeding risk
Rivaroxaban20mg daily with food; 15mg if CrCl 15-50Active bleeding, mechanical valveCr annually$$Once daily; must take with food
Dabigatran150mg BID; 75mg BID if CrCl 15-30Mechanical valve, CrCl under 15Cr annually$$Has reversal agent; higher GI bleeding
WarfarinDose to INR 2-3Active bleeding, poor complianceINR weekly then monthly$Required for mechanical valve or severe MS
Metoprolol succinate25-200mg dailyDecompensated HF, HR under 50, severe asthmaHR, BP$First-line rate control; safe in HFrEF
Diltiazem ER120-360mg dailyHFrEF, concurrent BBHR, BP$Good rate control; avoid in HFrEF

Rate control targets: lenient (HR under 110 at rest) for most patients; strict (HR under 80) for HFrEF or symptomatic despite lenient control.

Rhythm control options include cardioversion, antiarrhythmics (flecainide, propafenone, sotalol, amiodarone), and catheter ablation. Ablation success is 70-80% for paroxysmal AF. CASTLE-AF showed ablation reduced mortality in HFrEF.

Patient counseling points#

For anticoagulation: The blood thinner is the most important medicine for AFib because it prevents strokes. Take it every day at the same time. Tell every doctor and dentist you are on a blood thinner.

For rate control: The beta-blocker slows your heart rate. You may feel tired at first but this usually improves. Do not stop suddenly.

For lifestyle: Losing weight is one of the most effective things you can do. Alcohol is a common trigger. If you snore, you may need a sleep study.

Monitoring and follow-up#

Initial phase: follow-up 2-4 weeks after starting rate control; verify anticoagulation adherence; recheck Cr at 1 month if started DOAC.

Stable phase: follow-up every 3-6 months; annual Cr, CBC, TSH; echo if symptoms change.

Patient education#

What is this condition?#

Your heart has four rooms. The top two rooms should squeeze in rhythm. In AFib, the top rooms quiver instead of squeeze. This makes your heart beat fast and not in rhythm. The main worry is stroke. When the top rooms quiver, blood can pool and form clots.

What you can do#

Take your blood thinner every day. This is the most important pill. Do not skip doses. Lose weight if you need to. Cut back on alcohol. Check your pulse sometimes.

When to seek care#

Call your doctor if your heart races more than usual or you feel more tired or short of breath. Call 911 if you have signs of stroke: face drooping, arm weakness, trouble speaking. Call 911 for bad chest pain or if you pass out.

Questions to ask your doctor#

What is my stroke risk score? Which blood thinner is best for me? Should I try to get my heart back in rhythm? Do I need a sleep study?

Prognosis and monitoring#

Expected course#

With treatment, most patients achieve good symptom control. Stroke risk is reduced by 65% with anticoagulation. Without treatment, there is 5-fold increased stroke risk and progressive atrial remodeling.

Monitoring parameters#

Check heart rate every visit targeting under 110 at rest. Check BP every visit targeting under 130/80. Check Cr annually for DOAC dosing. Check TSH annually.

Complications to watch for#

Stroke or TIA: even with anticoagulation, residual risk is 1-2% per year. Educate on FAST symptoms. Heart failure from tachycardia-induced cardiomyopathy if rates uncontrolled. Bleeding risk is 2-3% per year on anticoagulation.

Special populations#

Elderly/geriatric#

Age alone is NOT a contraindication to anticoagulation. Elderly have higher stroke risk AND higher bleeding risk, but net clinical benefit of anticoagulation is GREATER in elderly. Apixaban is preferred for lowest bleeding risk. Fall risk: even patients who fall frequently benefit from anticoagulation. Start lower doses of rate control agents. Beers criteria: avoid digoxin doses over 0.125mg daily; avoid amiodarone if possible.

Chronic kidney disease#

DOAC dosing in CKD: Apixaban 5mg BID if CrCl 30-50, 2.5mg BID if CrCl 15-29. Rivaroxaban 15mg daily if CrCl 15-50. Dabigatran 75mg BID if CrCl 15-30. Warfarin may be preferred in severe CKD or dialysis. Monitor Cr more frequently. CKD patients have higher stroke AND bleeding risk but anticoagulation is still beneficial.

Other populations#

Heart failure: use beta-blockers for rate control in HFrEF; avoid CCBs. Rhythm control may improve EF per CASTLE-AF. Valvular AF with moderate-severe mitral stenosis or mechanical valve requires warfarin only. Polypharmacy: DOACs have fewer drug interactions than warfarin but still check P-gp inhibitors. Avoid combining anticoagulation with antiplatelet unless clear indication.

When to refer#

Specialist referral criteria#

Cardiology or EP referral routine (2-4 weeks): new AF for rhythm control discussion, symptomatic despite rate control, consideration for ablation, young patient under 65.

Cardiology referral urgent (within 1 week): difficult rate control despite multiple agents, recurrent symptomatic AF after cardioversion, new or worsening HF symptoms.

Urgency levels#

New AF stable and rate controlled: routine referral, start anticoagulation. Stable on rate control plus anticoagulation: PCP management. Symptomatic despite rate control: urgent cardiology. AF with hemodynamic instability: emergent ED.

Smartphrase snippets#

AF, stable on rate control: Atrial fibrillation, rate controlled on metoprolol 50mg daily, HR 78. On apixaban 5mg BID for stroke prevention (CHA2DS2-VASc 3), no bleeding complications. Continue current regimen; f/u 6 months.

AF, suboptimal rate control: Atrial fibrillation with inadequate rate control, HR 112 at rest, symptomatic with fatigue and palpitations. Increasing metoprolol from 50mg to 100mg daily, continue apixaban. Recheck in 2-4 weeks; cardiology referral if still symptomatic.

AF, new diagnosis: New diagnosis atrial fibrillation confirmed on ECG, CHA2DS2-VASc 4. Started apixaban 5mg BID and metoprolol 25mg daily; echo ordered. Discussed stroke prevention and lifestyle modification; cardiology referral placed, f/u 2-4 weeks.

Backward Test Valid Condition Heart Failure Forward